EVEON Accelerates its Developments and Expands its Range of Medical Devices

EVEON positions itself as a key player to make easily accessible new molecules, particularly biologics, to the largest number of people.

EVEON also enables administration methods that make life easier for patients by contributing to new care pathways. The challenges induced by healthcare reimbursement systems can be reduced by medical devices more innovative and adapted for patients and healthcare professionals.

EVEON focuses on the design, development and industrialization, with its partners of the JBT HubUp alliance, of upgraded medical devices for both drug preparation and drug delivery. EVEON offers tailor-made solutions for applications at home or in a medical environment, based on a unique technology platform Intuity®. Safety and ease of use are the basis of its developments.

In 2019, EVEON produced the first functional models of Intuity® Ject, reaching a new stage in its development and growth. Different versions of this device are being prepared for reconstitution and injection of drugs. EVEON has also developed, based on its patented technologies, a new automated medical spray device, Intuity® Spray, for the delivery of high viscosity treatments through the respiratory, dermatological or oral routes. These devices are in addition to the Intuity® Mix device that allows the automatic reconstitution of lyophilized drugs.

At the end of 2019, Forbes magazine ranked EVEON 3rd most inventive company in France in the medical technologies category.

“In 2019, with the confidence of our customers and the mobilization of our teams and partners, we have reached new milestones and accelerated our developments. Thanks to these innovations, we are already planning new evolutions in 2020 for EVEON both in terms of technology and of overall performance,” said Vincent TEMPELAERE, CEO of EVEON.

 

SourceEVEON

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”